Science Explorer Back to mapMap
Discussion
Company · Birmingham · United States

Gem Pharmaceuticals (United States)

gempharmltd.co.ukROR OpenAlex
Research works
5
▼ 100% vs 2018-21
Citations
200
40.0 per fractional work
Top-10% rate
15.4%
all institutions 10.0%
Open access
50%
world 40%
International
16%
world 18%
Gem Pharmaceuticals (United States)

Not ranked overall: Gem Pharmaceuticals (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Gem Pharmaceuticals (United States) work in?

In all years, 63% of research at Gem Pharmaceuticals (United States) is in Health Sciences, 34% in Life Sciences. Its largest fields are Medicine (59%), Biochemistry, Genetics and Molecular Biology (25%), Chemistry (4%). It does 1.5× the world's share of Health Sciences.

Health Sciences: 3 fractional works · 62.6% of its workMedicine: 3 fractional works · 59.2% of its workCardiology and Cardiovascular Medicine: 1 fractional works · 17.0% of its workOncology: 1 fractional works · 15.8% of its workEpidemiology: 0 fractional works · 5.6% of its workComplementary and alternative medicine: 0 fractional works · 4.4% of its workGenetics: 0 fractional works · 3.4% of its workDermatology: 0 fractional works · 2.4% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 2.2% of its workPediatrics, Perinatology and Child Health: 0 fractional works · 2.2% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 2.2% of its workPulmonary and Respiratory Medicine: 0 fractional works · 1.8% of its workPathology and Forensic Medicine: 0 fractional works · 1.4% of its workPhysiology: 0 fractional works · 0.8% of its workNursing: 0 fractional works · 2.2% of its workNutrition and Dietetics: 0 fractional works · 2.2% of its workVeterinary: 0 fractional works · 1.2% of its workSmall Animals: 0 fractional works · 1.2% of its workLife Sciences: 2 fractional works · 33.6% of its workBiochemistry, Genetics and Molecular Biology: 1 fractional works · 25.0% of its workMolecular Biology: 1 fractional works · 12.0% of its workCancer Research: 0 fractional works · 5.0% of its workBiophysics: 0 fractional works · 4.6% of its workGenetics: 0 fractional works · 3.4% of its workNeuroscience: 0 fractional works · 3.4% of its workCellular and Molecular Neuroscience: 0 fractional works · 3.4% of its workAgricultural and Biological Sciences: 0 fractional works · 2.2% of its workPlant Science: 0 fractional works · 2.2% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 1.6% of its workToxicology: 0 fractional works · 1.6% of its workImmunology and Microbiology: 0 fractional works · 1.4% of its workImmunology: 0 fractional works · 1.4% of its workPhysical Sciences: 0 fractional works · 3.8% of its workChemistry: 0 fractional works · 3.8% of its workOrganic Chemistry: 0 fractional works · 3.8% of its workALL ITS WORKGemPharmaceuticals…5fractional works, all years
Life Sciences34%Physical Sciences4%Health Sciences63%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 9 fields, with their numbers
    1. Medicine359.2%
    2. Nursing02.2%
    3. Veterinary01.2%
    1. Biochemistry, Genetics and Molecular Biology125.0%
    2. Neuroscience03.4%
    3. Agricultural and Biological Sciences02.2%
    4. Pharmacology, Toxicology and Pharmaceutics01.6%
    5. Immunology and Microbiology01.4%
    1. Chemistry03.8%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

    What are the most cited papers from Gem Pharmaceuticals (United States)?

    The most cited paper from Gem Pharmaceuticals (United States) is "Bcl-xL regulates metabolic efficiency of neurons through interaction with the mitochondrial F1FO ATP synthase" (Kambiz N. Alavian, Hongmei Li, Leon P. Collis et al., 2011), with 284 citations. Next come "Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma" (104) and "The Psychosocial Aspects of Complementary and Alternative Medicine" (82).

    Most cited papers
    #PaperReleasedCitations
    1 Bcl-xL regulates metabolic efficiency of neurons through interaction with the mitochondrial F1FO ATP synthase Kambiz N. Alavian, Hongmei Li, Leon P. Collis et al. · Nature Cell Biology Open access 18 Sep 2011 284
    2 Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma Jimmy J. Hwang, John G. Kuruvilla, David S. Mendelson et al. · Clinical Cancer Research Open access 10 Jun 2010 104
    3 The Psychosocial Aspects of Complementary and Alternative Medicine Jacintha S. Cauffield · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy Nov 2000 82
    4 Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms LesterI. Harrison, ShariL. Skinner, ThomasC. Marbury et al. · Archives of Dermatological Research 8 Apr 2004 77
    5 Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer Corey Jay Langer, Istvan U. Albert, Helen J. Ross et al. · Lung Cancer 13 May 2014 71
    All 15 most cited papers, with filters and sorting

    Which research topics does Gem Pharmaceuticals (United States) publish most on?

    By volume: Chemotherapy-induced cardiotoxicity and mitigation, Cancer Treatment and Pharmacology, Cancer, Hypoxia, and Metabolism and Chronic Lymphocytic Leukemia Research.

    Chemotherapy-induced car…1Chemotherapy-induced cardiotoxicity and mitigation: 1 fractional worksCancer Treatment and Pha…0Cancer Treatment and Pharmacology: 0 fractional worksCancer, Hypoxia, and Met…0Cancer, Hypoxia, and Metabolism: 0 fractional worksChronic Lymphocytic Leukemia Research: 0 fractional worksBlood disorders and treatments: 0 fractional worksElectron Spin Resonance Studies: 0 fractional worksNuclear Receptors and Signaling: 0 fractional worksHistone Deacetylase Inhi…0Histone Deacetylase Inhibitors Research: 0 fractional worksSynthesis and Biological…0Synthesis and Biological Evaluation: 0 fractional worksAutophagy in Disease and…0Autophagy in Disease and Therapy: 0 fractional works
    Cardiology and Cardiovascular MedicineOncologyCancer ResearchGenetics5 others

    Area is fractional works; colour is the subfield each topic belongs to.

    1. 1 Chemotherapy-induced cardiotoxicity and mitigation Cardiology and Cardiovascular Medicine 1 works
    2. 2 Cancer Treatment and Pharmacology Oncology 0 works
    3. 3 Cancer, Hypoxia, and Metabolism Cancer Research 0 works
    4. 4 Chronic Lymphocytic Leukemia Research Genetics 0 works
    5. 5 Blood disorders and treatments Genetics 0 works
    6. 6 Electron Spin Resonance Studies Biophysics 0 works
    7. 7 Nuclear Receptors and Signaling Cellular and Molecular Neuroscience 0 works
    8. 8 Histone Deacetylase Inhibitors Research Molecular Biology 0 works
    9. 9 Synthesis and Biological Evaluation Organic Chemistry 0 works
    10. 10 Autophagy in Disease and Therapy Epidemiology 0 works

    How open and international is its research?

    Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

    openly available50.3%not open49.7%

    World: 40% of research is openly available.

    with international co-authors15.9%domestic only84.1%

    World: 18% is written across borders.

    How has Gem Pharmaceuticals (United States)'s research output changed?

    Output in 2022-2025 was 100% lower than in 2018-2021.

    200520102015
    grewheldshrank

    The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

    Its share of all research

    Growing output can still be a shrinking share: all of science grows. This is Gem Pharmaceuticals (United States) as a percentage of every work published that year, 0.000014% in 2016.

    0.000020%0.000040%0.000060%Gem Pharmaceuticals (United States)0.0000044% in 20192010

    Fractional works of Gem Pharmaceuticals (United States) over all fractional works that year. How the balance of science has shifted.

    Other research institutions in Birmingham

    All research institutions in Birmingham

    Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

    Discussion

    Ask a question or share a note about Gem Pharmaceuticals (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.